http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-102163494-B1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D498-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D498-16 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D498-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-395 |
| filingDate | 2018-10-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2020-10-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2020-10-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-102163494-B1 |
| titleOfInvention | heteroaromatic macrocyclic derivatives as protein kinase inhibitors |
| abstract | The present invention provides a 2,7-substituted cyano[3,2- d ]pyrimidine cyclized compound having protein kinase inhibitory activity, a pharmaceutically acceptable salt thereof, and abnormal cells containing the compound as an active ingredient. It relates to a pharmaceutical composition for the prevention, alleviation or treatment of diseases caused by growth, and the novel 2,7-substituted cyano[3,2- d ]pyrimidine cyclized compound of the present invention is used for growth factor signaling Since it exhibits an excellent inhibitory effect on various protein kinases involved, it is useful as a prevention, alleviation or therapeutic agent for abnormal cell growth diseases caused by these protein kinases. |
| priorityDate | 2018-10-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 649.